Quest Partners LLC Exelixis, Inc. Transaction History
Quest Partners LLC
- $920 Billion
- Q1 2025
A detailed history of Quest Partners LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 961 shares of EXEL stock, worth $41,005. This represents 0.0% of its overall portfolio holdings.
Number of Shares
961
Previous 15,115
93.64%
Holding current value
$41,005
Previous $503 Million
92.95%
% of portfolio
0.0%
Previous 0.07%
Shares
6 transactions
Others Institutions Holding EXEL
# of Institutions
613Shares Held
257MCall Options Held
1.57MPut Options Held
730K-
Black Rock Inc. New York, NY33.5MShares$1.43 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.22 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$962 Million4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$633 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$503 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $13.7B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...